Bezlotoxumab for the prevention of Clostridium difficile recurrence

References

• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.
   PubMed Web of Science ®Google Scholar
• Abrahamian FM, Talan DA, Krishnadasan A, et al. Clostridium difficile infection among US emergency department patients with diarrhea and no vomiting. Ann Emerg Med. [Internet]. 2017;70:19-27.e4.
   PubMed Web of Science ®Google Scholar
• National strategy for combating antibiotic-resistant bacteria. Centers for Disease Control and Prevention. Washington, DC; 2014 [cited 2017 May 13]. Available from: https://www.cdc.gov/drugresistance/pdf/carb_national_strategy.pdf
   Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372:825–834.
   PubMed Web of Science ®Google Scholar
• Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526–536.
   PubMed Web of Science ®Google Scholar
• Lyras D, O’Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009;458:1176–1179.
   PubMed Web of Science ®Google Scholar
• Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467:711–713.
   PubMed Web of Science ®Google Scholar
• Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc. 2010;58:1556–1564.
   PubMed Web of Science ®Google Scholar
• Collini PJ, Bauer M, Kuijper E, et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J. Infect. 2012;64:131–147.
   PubMed Web of Science ®Google Scholar
• Gupta SB, Mehta V, Dubberke ER, et al. Antibodies to toxin B are protective against Clostridium difficile infection recurrence. Clin Infect Dis. 2016;63:730–734.
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397.
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189–193.
   PubMed Web of Science ®Google Scholar
• Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472.
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis. 2012;55(Suppl 2):S65–S70.
   PubMed Web of Science ®Google Scholar
• Pépin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005;173:1037–1042.
   PubMed Web of Science ®Google Scholar
• van Beurden YH, Bomers MK, van der Werff SD, et al. Cost analysis of an outbreak of Clostridium difficile infection ribotype 027 in a Dutch tertiary care centre. J Hosp Infect. [Internet]. 2016. DOI:10.1016/j.jhin.2016.12.019
   PubMed Web of Science ®Google Scholar
• Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–1084.
   PubMed Web of Science ®Google Scholar
• See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58:1394–1400.
   PubMed Web of Science ®Google Scholar
• Pépin J, Saheb N, Coulombe MA. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. [Internet]. 2005;41:1254–1260. Available from: http://cid.oxfordjournals.org/content/41/9/1254.short
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(Suppl 2):S88–S92.
   PubMed Web of Science ®Google Scholar
• Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, et al. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis. 2016;62:574–580.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769–1775.
   PubMed Web of Science ®Google Scholar
• Carignan A, Poulin S, Martin P, et al. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016;111:1834–1840.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–431.
   PubMed Web of Science ®Google Scholar
• Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59:345–354.
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–317.
   PubMed Web of Science ®Google Scholar
• Rodrigues R, Barber GE, Ananthakrishnan AN. A comprehensive study of costs associated with recurrent Clostridium difficile infection. Infect Control Hosp Epidemiol. 2017;38:196–202.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis. 2012;55(Suppl 2):S132–S142.
   PubMed Web of Science ®Google Scholar
• Lewis BB, Buffie CG, Carter RA, et al. Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole. J Infect Dis. 2015;212:1656–1665.
   PubMed Web of Science ®Google Scholar
• Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008;197:435–438.
   PubMed Web of Science ®Google Scholar
• Leav BA, Blair B, Leney M, et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28:965–969.
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478–498; quiz 499.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
   PubMed Web of Science ®Google Scholar
• Pharmacia Inc. Metronidazole product monograph. Chicago: Pharmacia; 2003 [cited 2017 May 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/12623slr059_flagyl_lbl.pdf
   Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KMLST, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302–307.
   PubMed Web of Science ®Google Scholar
• Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. [Internet]. 2017;177:546.
   PubMed Web of Science ®Google Scholar
• Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. Jama. 2015;313:398–408.
   PubMed Web of Science ®Google Scholar
• Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017;3:CD004610.
   PubMed Web of Science ®Google Scholar
• Gonzales M, Pepin J, Frost EH, et al. Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis. 2010;10:363.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281–289.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(Suppl 2):S154–S161.
   PubMed Web of Science ®Google Scholar
• Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440–447.
   PubMed Web of Science ®Google Scholar
• Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108:500–508.
   PubMed Web of Science ®Google Scholar
• Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994–1002.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–415.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–843.
   PubMed Web of Science ®Google Scholar
• Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017;64:265–271.
   PubMed Web of Science ®Google Scholar
• Di Bella S, Gouliouris T, Petrosillo N. Fecal microbiota transplantation (FMT) for Clostridium difficile infection: focus on immunocompromised patients. J Infect Chemother. 2015;21:230–237.
   PubMed Web of Science ®Google Scholar
• Kelly CR, Ihunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065–1071.
   PubMed Web of Science ®Google Scholar
• Center for Biologics Evaluation and Research.Guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. Silver Spring, MD: U.S. Department of Health and Human Services Food and Drug Administration; 2013 [cited 2017 May 13]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM361393.pdf
   Google Scholar
• Babcock GJ, Broering TJ, Hernandez HJ, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74:6339–6347.
   PubMed Web of Science ®Google Scholar
• Corthier G, Muller MC, Wilkins TD, et al. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991;59:1192–1195.
   PubMed Web of Science ®Google Scholar
• Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun. 1998;66:2018–2025.
   PubMed Web of Science ®Google Scholar
• Warny M, Vaerman JP, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun. 1994;62:384–389.
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001;69:988–995.
   PubMed Web of Science ®Google Scholar
• Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003;71:1608–1610.
   PubMed Web of Science ®Google Scholar
• Merck & Co Inc. Zinplava package insert. Kenilworth, NJ: Merck & Co., Inc; 2016 [cited 2017 May 13]. Available from: https://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf
   Google Scholar
• Zhang Z, Chen X, Hernandez LD, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015;83:405–416.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. BLA 761046: bezlotoxumab injection Antimicrobial Drugs Advisory Committee (AMDAC) Advisory Committee (AC) meeting. Food and Drug Administration;2016 [cited 2017 May 13]. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm505291.pdf
   Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
   PubMed Web of Science ®Google Scholar
• Deng R, Jin F, Prabhu S, et al. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol. 2012;8:141–160.
   PubMed Web of Science ®Google Scholar
• Kyne L. Clostridium difficile–beyond antibiotics. N Engl J Med. 2010;362:264–265.
   PubMed Web of Science ®Google Scholar
• Warn P, Thommes P, Sattar A, et al. Disease progression and resolution in rodent models of Clostridium difficile infection and impact of antitoxin antibodies and vancomycin. Antimicrob Agents Chemother. 2016;60:6471–6482.
   PubMed Web of Science ®Google Scholar
• Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289:18008–18021.
   PubMed Web of Science ®Google Scholar
• Koon HW, Shih DQ, Hing TC, et al. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother. 2013;57:3214–3223.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822–831.
   PubMed Web of Science ®Google Scholar
• Hernandez LD, Racine F, Xiao L, et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015;59:1052–1060.
   PubMed Web of Science ®Google Scholar
• Džunková M, D’Auria G, Xu H, et al. The monoclonal antitoxin antibodies (actoxumab-bezlotoxumab) treatment facilitates normalization of the gut microbiota of mice with Clostridium difficile infection. Front Cell Infect Microbiol. 2016;6:119.
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Tummala S, Molrine D, et al. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine. 2008;26:3404–3409.
   PubMed Web of Science ®Google Scholar
• Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC). FDA briefing document – bezlotoxumab injection. Silver Spring, MD: U.S. Department of Health and Human Services Food and Drug Administration: Center for Drug Evaluation and Research; 2016 [cited 2017 May 13]. Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm505290.pdf
   Google Scholar
• Wilcox MH, Rahav G, Dubberke E, et al. [Poster]. P1341: assessment of efficacy of bezlotoxumab for prevention of Clostridium difficile infection recurrence by diagnostic test method. Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2016; Amsterdam, The Netherlands; April 09-12, 2016 [cited 2017 May 13]. Available from: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=50078
   Google Scholar
• Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin Microbiol Infect. 2012;18(Suppl 6):21–27.
   PubMed Web of Science ®Google Scholar
• Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One. 2013;8:e76269.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Application Number: 761046Orig1s000, Approval Letter. Silver Spring, MD: U.S. Department of Health and Human Services Food and Drug Administration; 2016 [cited 2017 May 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761046Orig1s000Approv.pdf
   Google Scholar
• Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18(Suppl 6):5–12.
   PubMed Web of Science ®Google Scholar
• Ghantoji SS, Sail K, Lairson DR, et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74:309–318.
   PubMed Web of Science ®Google Scholar
• Shah DN, Aitken SL, Barragan LF, et al. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016;93:286–289.
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Schaefer E, Reske KA, et al. Attributable inpatient costs of recurrent Clostridium difficile infections. Infect Control Hosp Epidemiol. 2014;35:1400–1407.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Jesdale WM, et al. Recurrent Clostridium difficile infection among Medicare patients in nursing homes: a population-based cohort study. Medicine. 2017;96:e6231.
   PubMed Web of Science ®Google Scholar
• Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015;14:737–738.
   PubMed Web of Science ®Google Scholar
• Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics – a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.
   PubMed Web of Science ®Google Scholar
• Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. [Internet]. 2017. DOI:10.1053/j.gastro.2017.02.003
   Web of Science ®Google Scholar
• Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
   PubMed Web of Science ®Google Scholar